Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

180 Life Sciences’ Woody Sets Out Vision For Repurposing Anti-TNF Biologics

CEO Expands On Recent Announcement Of Collaboration With Celltrion

Executive Summary

After 180 Life Sciences recently struck a deal with Korea’s Celltrion to support its work in repurposing off-patent biologics, CEO Jim Woody speaks to Generics Bulletin about what the collaboration means for the company and its next steps.

You may also be interested in...



Following Positive IIb Study Data, Can 180 Life Sciences Clear The Next Regulatory Hurdle?

180 Life Sciences has found that adalimumab can effectively treat nodule hardness and size in Dupuytren’s disease during a Phase IIb study. But, the company’s CEO Jim Woody tells Generics Bulletin, regulators in the UK and US have requested more information before they will press on with authorization.

180 Life Sciences Adalimumab Study Publishes Positive IIb Dupuytren’s Disease Data

Adalimumab could find itself with a tenth official indication, after 180 Life Sciences found that it was able to effectively treat nodule hardness and size in Dupuytren’s disease during a phase IIb study.

Generics Bulletin Editor’s Picks For Q4 2021

As 2021 drew to a close, there was no shortage of exciting developments for the off-patent industry. Alongside news of a strategic review affecting one of the biggest generics and biosimilars players, Generics Bulletin also held its annual Global Generics & Biosimilars Awards and brought readers fresh and exclusive insights from top industry executives.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151347

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel